Mavrostobart vs Oleclumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: CD73 · full Non-Small Cell Lung Cancer pipeline
Mavrostobart
Developed by Phanes Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT05431270 (registry estimate)
No aligned efficacy figure on record for this race.
Oleclumab
Developed by MedImmune LLC
NCT03822351 · Phase 2 · completed
Participants were randomized among three treatment groups, including durvalumab monotherapy as the comparator, but the study was open-label rather than blinded; 60 participants received durvalumab plus oleclumab and 67 received durvalumab alone. The clinical primary endpoint, RECIST 1.1 objective response rate, was numerically higher with oleclumab, but statistical significance of the comparison was not reported, so the result remains unclear.
Next expected readout: January 2027 · NCT05221840 (registry estimate)
Reported efficacy
Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint): Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint): Control Arm (Durvalumab Monotherapy) 23.9% (95% CI 14.3-35.9) vs Arm A (Durvalumab + Oleclumab) 35.0% (95% CI 23.1-48.4) vs Arm B (Durvalumab + Monalizumab) 40.3% (95% CI 28.1-53.6) (unclear)
Result source: NCT03822351
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Mavrostobart | Oleclumab |
|---|---|---|
| PFS, median | —Not reported | 21.1 vs 7.3vs Durvalumab MonotherapyNCT03822351 |
| OS, median | —Not reported | —Trial running · NCT05221840 |
| ORR | —Not reported | 35% vs 23.9%vs Durvalumab MonotherapyNCT03822351 |
| Duration of response, median | —Not reported | 29.9NCT03822351 |
PFS, median
- Mavrostobart
- —Not reported
- Oleclumab
- 21.1 vs 7.3vs Durvalumab MonotherapyNCT03822351
OS, median
- Mavrostobart
- —Not reported
- Oleclumab
- —Trial running · NCT05221840
ORR
- Mavrostobart
- —Not reported
- Oleclumab
- 35% vs 23.9%vs Durvalumab MonotherapyNCT03822351
Duration of response, median
- Mavrostobart
- —Not reported
- Oleclumab
- 29.9NCT03822351
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Mavrostobart: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Mavrostobart: 0 of 4 rows · Oleclumab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Oleclumab |
|---|---|
| Dropout rate | 51.7%Arm A (Durvalumab + Oleclumab)a NCT03822351 · Phase 2 · combination show 3 more results—Durvalumab + Oleclumab NCT03822351 · Phase 2 · combination 3.7%1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence 14.3%1500 mg + 3000 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —Arm A (Durvalumab + Oleclumab)a NCT03822351 · Phase 2 · combination show 3 more results—Durvalumab + Oleclumab NCT03822351 · Phase 2 · combination —1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence —1500 mg + 3000 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | —Arm A (Durvalumab + Oleclumab)a NCT03822351 · Phase 2 · combination show 3 more results33.9%Durvalumab + Oleclumab NCT03822351 · Phase 2 · combination 11.5%1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence 9.5%1500 mg + 3000 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | show 2 more results1500 mg fatigue 23.1% procedural pain 19.2% asthenia 11.5% NCT03794544 · Phase 2 · registry result, not featured evidence 1500 mg + 3000 mg fatigue 19% asthenia 14.3% cough 14.3% NCT03794544 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Oleclumab
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mavrostobart's landscape · Oleclumab's landscape